Corresponding author:
Flora T Musuamba
Belgian Federal Agency for Medicines and Health Products, B-1060
Brussels, Belgium
flora.musuambashinanu@afmps.be
Principal Investigator statement: The authors confirm that
there is no principal investigator in this study because this study only
includes observational data from standard clinical practice data.
Conflict of interest: The authors declared no competing
interest for this work.
Data availability statement : The data that support the findings
of this study are available on request from the corresponding author.
The data are not publicly available due to privacy or ethical
restrictions.
Word count: Abstract: 250/ Text: 2988
Table count : 3
Figure count : 3
Keywords: Hydroxychloroquine, modelling and simulations, dosing
rationale, dosing optimization, pharmacokinetics
Running title: Hydroxychloroquine dosing in COVID-19 patients